Vazegepant hydrochloride

Description: Vazegepant hydrochloride (Vazegepant HCl) is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study. Target: CGRP Receptor. Smiles: Cl.CN1CCC(CC1)N1CCN(CC1)C(=O)[C@@H](Cc1cc(C)c2[nH]ncc2c1)NC(=O)N1CCC(CC1)c1cc2ccccc2[nH]c1=O. References: Moreno-Ajona D , Abigail Pérez-Rodríguez, Goadsby P J . Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?[J]. Current Opinion in Neurology, 2020, 33(3):1.